ABSTRACT
Donor lymphocyte infusions (DLI) have rapidly become established as an important treatment for patients who relapse after an allogeneic progenitor cell transplant [1-3]. The dramatic responses seen primarily in chronic myelogenous leukemia (CML) but also on occasions in other hematologic malignancies after DLI represent the most direct evidence of a graft-versus-leukemia (GVL) effect mediated by donor lymphocytes [2,3].
